If approved, a new seasonal flu shot would become the first commercially available flu vaccine using mRNA technology, according to a news release. Moderna’s seasonal influenza vaccine mRNA-1010 (marketed as mFlusiva) has not yet received final Food and Drug Administration (FDA) approval, but it has reached a major milestone. On June 18, the agency’s vaccine committee voted unanimously that the mRNA vaccine’s benefits outweigh its risks for adults aged 50 years and older, as published …
Read More